AbbVie is buying Botox maker Allergan in a cash-and-stock deal valued at about $63 billion.
The maker of the blockbuster immune disorder treatment Humira said Tuesday that it will pay $120.30 in cash and a portion of AbbVie stock for each Allergan share. That amounts to $188.24 per share, or a 45% premium to Allergan's closing price Monday.
Shares of Allergan Plc, based in Dublin, Ireland, jumped nearly 30% before the opening bell.
AbbVie shareholders will own 83% of the specialty drug company combination after the deal's completion while Allergan shareholders will have a 17% stake.
U.S. & World
Stories that affect your life across the U.S. and around the world.
Regulators and Allergan shareholders still have to approve the deal.
Shares of AbbVie Inc., based in North Chicago, Illinois, sank 10%.